Sanofi shares results from phase 2 trial for frexalimab in MS treatment

Betsy Goodfellow | July 1, 2024 | News story | Research and Development MS, Neurology, Sanofi, multiple sclerosis 

Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for the treatment of patients with relapsing multiple sclerosis (MS).

The results showed a significant reduction in plasma levels of neurofilament light chain (NfL) after one year of treatment, which is a biomarker of nerve cell damage, typically raised in patients with MS.

Full results were presented at the 10th Congress of the European Academy of Neurology (EAN) in Helsinki, Finland. The results support the progression of the programme to phase 3 studies for the delay of disability progression.

Advertisement

According to the results of this study, participants receiving high-doses of the drug experienced a 41% reduction in plasma NfL levels form baseline to week 48, and patients in the lower-dose group experienced a 35% reduction on plasma NfL levels from baseline to week 48.

Erik Wallström MD PhD, global head of neurology development at Sanofi, commented: “People with multiple sclerosis need new high-efficacy treatment options that target disability progression, which remains an unmet need. These results, alongside the previously reported phase 2 efficacy and safety results, further show that frexalimab’s novel mechanism of action has the potential to deliver meaningful improvements for people living with this chronic and debilitating disease.”

Betsy Goodfellow

Related Content

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …

Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition

The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …

sanofi

Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline

Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …

The Gateway to Local Adoption Series

Latest content